title: Neonatal effects of magnesium sulfate given to the mother.
abstract: OBJECTIVE
  Magnesium historically has been used for treatment and/or prevention of eclampsia or preterm labor. More recently, antepartum magnesium sulfate has been suggested for prevention of cerebral palsy in preterm infants. Although adverse effects and toxicity of magnesium in pregnant women are well known, the fetal-neonatal effects of magnesium are less clear. The objective of this study was to evaluate the effects of magnesium on the newborn infant.
  
  
  METHODS
  This is a retrospective cohort analysis of women who received antepartum magnesium sulfate for prevention or treatment of eclampsia. Magnesium sulfate was given intravenously beginning with a 6-g dose, followed by 2- to 3-g/h infusion. Newborn hypotonia was diagnosed if an infant exhibited less than normal tone/activity upon admission to the nursery.
  
  
  RESULTS
  Between January 2000 and February 2009, a total of 6654 women with preeclampsia were treated with intravenous magnesium sulfate as described; 88 (6%) of the infants were diagnosed with hypotonia. Lower 1-minute and 5-minute Apgar scores, intubation in the delivery room, admission to special care nursery, and hypotonia were all significantly increased as maternal serum magnesium concentrations increased before birth.
  
  
  CONCLUSIONS
  Several neonatal complications are significantly related to increasing concentrations of magnesium in the maternal circulation.
authors: Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9032, USA.
authors: Mina
authors: M
authors: Abbassi-Ghanavati
authors: James M
authors: JM
authors: Alexander
authors: Donald D
authors: DD
authors: McIntire
authors: Rashmin C
authors: RC
authors: Savani
authors: Kenneth J
authors: KJ
authors: Leveno
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001034:Apgar Score; D015331:Cohort Studies; D003710:Demography; D004334:Drug Administration Schedule; D004461:Eclampsia / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008274:Magnesium / Q000097:blood; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D008431:Maternal-Fetal Exchange; D009123:Muscle Hypotonia / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D011225:Pre-Eclampsia / Q000097:blood / Q000188:drug therapy / Q000208:ethnology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011297:Prenatal Exposure Delayed Effects; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
chemical_list: D000927:Anticonvulsants; D008278:Magnesium Sulfate; D008274:Magnesium